<div class="govuk-grid-row">
  <div class="govuk-grid-column-two-thirds">
    <div class="gem-c-title govuk-!-margin-top-8 govuk-!-margin-bottom-8">
    <span class="govuk-caption-xl gem-c-title__context">
      Guidance
    </span>
  <h1 class="gem-c-title__text gem-c-title__text--long">
    Converting Parallel Distribution Notices (PDNs) to UK Parallel Import Licences (PILs) from 1 January 2021
  </h1>
</div>
  </div>
  
  <div class="govuk-grid-column-two-thirds">
    
  <p class="gem-c-lead-paragraph">The process to convert Parallel Distribution Notices (PDNs) into Parallel Import Licences (PILs) from 1 January 2021.</p>

  </div>
</div>

<div class="govuk-grid-row">
  <div class="metadata-logo-wrapper">
    <div class="govuk-grid-column-two-thirds metadata-column">
        <div class="app-c-publisher-metadata" lang="en">
    <div class="app-c-published-dates " lang="en">
    Published 1 September 2020
</div>

      <div class="app-c-publisher-metadata__other">
        <dl data-module="track-click">
            <dt class="app-c-publisher-metadata__term">
              From:
            </dt>
            <dd class="app-c-publisher-metadata__definition" data-module="gem-toggle">
                <span class="app-c-publisher-metadata__definition-sentence">
                  <a class="govuk-link" href="/government/organisations/medicines-and-healthcare-products-regulatory-agency">Medicines and Healthcare products Regulatory Agency</a>
                </span>
            </dd>
        </dl>
      </div>
  </div>

    </div>
    <div class="govuk-grid-column-one-third">
    </div>
  </div>
</div>



  <section class="app-c-header-notice" aria-label="notice" role="region">
    <div class="app-c-header-notice__header">
      <h2 class="app-c-header-notice__title">New rules for January 2021</h2>
    </div>

    <div class="app-c-header-notice__content">
          <p class="app-c-header-notice__text govuk-body">The UK has left the EU, and the transition period after Brexit comes to an end this year.</p>
          <p class="app-c-header-notice__text govuk-body">This page tells you what you'll need to do from 1 January 2021. It will be updated if anything changes.</p>
        <div class="app-c-header-notice__links">
            <p class="govuk-body app-c-header-notice__link-intro">
              For current information, read: 
              <a data-module="track-click" data-track-category="no_deal_notice" data-track-action="/guidance/medicines-apply-for-a-parallel-import-licence" data-track-label="Medicines: apply for a parallel import licence" class="app-c-header-notice__link" href="/guidance/medicines-apply-for-a-parallel-import-licence">Medicines: apply for a parallel import licence</a>
            </p>
        </div>

        <p class="app-c-header-notice__text govuk-body">You can also read about <a data-module="track-click" data-track-category="no_deal_notice" data-track-action="/transition" data-track-label="the transition period" class="govuk-link" href="/transition">the transition period</a>.</p>
    </div>
  </section>


<div class="govuk-grid-row">
  <div class="govuk-grid-column-two-thirds">
    

      <div id="contents" class="app-c-contents-list-with-body" data-module="sticky-element-container">
      <div class="responsive-bottom-margin">
          <nav class="gem-c-contents-list  gem-c-contents-list--no-underline " role="navigation" data-module="track-click">
      <h2 class="gem-c-contents-list__title">Contents</h2>

    <ol class="gem-c-contents-list__list">
        <li class="gem-c-contents-list__list-item gem-c-contents-list__list-item--dashed">
          <a class="gem-c-contents-list__link govuk-link " data-track-category="contentsClicked" data-track-action="content_item 1" data-track-label="#converting-parallel-distribution-notices-pdns-to-uk-parallel-import-licences-pils-from-1-january-2021" data-track-options="{"dimension29":"Converting Parallel Distribution Notices (PDNs) to UK Parallel Import Licences (PILs) from 1 January 2021"}" href="#converting-parallel-distribution-notices-pdns-to-uk-parallel-import-licences-pils-from-1-january-2021">Converting Parallel Distribution Notices (PDNs) to UK Parallel Import Licences (PILs) from 1 January 2021</a>

        </li>
        <li class="gem-c-contents-list__list-item gem-c-contents-list__list-item--dashed">
          <a class="gem-c-contents-list__link govuk-link " data-track-category="contentsClicked" data-track-action="content_item 2" data-track-label="#outline-of-the-process-for-converting-pdns-to-pils" data-track-options="{"dimension29":"Outline of the process for converting PDNs to PILs\n"}" href="#outline-of-the-process-for-converting-pdns-to-pils">Outline of the process for converting PDNs to PILs
</a>

        </li>
        <li class="gem-c-contents-list__list-item gem-c-contents-list__list-item--dashed">
          <a class="gem-c-contents-list__link govuk-link " data-track-category="contentsClicked" data-track-action="content_item 3" data-track-label="#detailed-description-of-the-process-for-convertingpdnstopils" data-track-options="{"dimension29":"Detailed description of the process for converting PDNs to PILs\n"}" href="#detailed-description-of-the-process-for-convertingpdnstopils">Detailed description of the process for converting PDNs to PILs
</a>

        </li>
        <li class="gem-c-contents-list__list-item gem-c-contents-list__list-item--dashed">
          <a class="gem-c-contents-list__link govuk-link " data-track-category="contentsClicked" data-track-action="content_item 4" data-track-label="#further-information" data-track-options="{"dimension29":"Further information"}" href="#further-information">Further information</a>

        </li>
    </ol>
</nav>
      </div>
    
      
<div class="gem-c-govspeak govuk-govspeak direction-ltr" data-module="govspeak">
      <div class="govspeak">
<h2 id="converting-parallel-distribution-notices-pdns-to-uk-parallel-import-licences-pils-from-1-january-2021">Converting Parallel Distribution Notices (<abbr title="Parallel Distribution Notices">PDNs</abbr>) to UK Parallel Import Licences (<abbr title="Parallel Import Licences">PILs</abbr>) from 1 January 2021</h2>

<p>At the end of the transition period, the UK will have in place arrangements for the continued authorisation of medicinal products.</p>

<h3 id="great-britain">Great Britain</h3>
<p>Parallel Distribution Notices will no longer be valid in Great Britain (England, Scotland, Wales) and will be replaced by Parallel Import Licences which will allow the products to be marketed in Great Britain only.</p>

<p>This guidance provides a detailed description of the process we have put in place to convert your Parallel Distribution Notices (<abbr title="Parallel Distribution Notices">PDNs</abbr>) into Parallel Import Licences (<abbr title="Parallel Import Licences">PILs</abbr>) for Great Britain at the end of the Transition Period.</p>

<h3 id="northern-ireland">Northern Ireland</h3>
<p>Parallel Distribution Notices will remain valid in Northern Ireland and no regulatory action is required to continue to market products directly imported from <abbr title="European Union">EU</abbr> into Northern Ireland only.</p>

<h2 id="outline-of-the-process-for-converting-pdns-to-pils">Outline of the process for converting <abbr title="Parallel Distribution Notices">PDNs</abbr> to <abbr title="Parallel Import Licences">PILs</abbr>
</h2>
<p><abbr title="Parallel Distribution Notice">PDN</abbr> holders are given the opportunity to opt-in to the conversion process for all or some of their <abbr title="Parallel Distribution Notices">PDNs</abbr> by notifying the <abbr title="Medicines and Healthcare products Regulatory Agency">MHRA</abbr> in writing as described below. This process requires minimal information from <abbr title="Parallel Distribution Notice">PDN</abbr> holders.</p>

<p>If you choose not to opt-in, following the end of the transition period your product(s) will no longer be licensed in Great Britain and you will no longer be able to place them on the market in Great Britain.</p>

<p><abbr title="Medicines and Healthcare products Regulatory Agency">MHRA</abbr> will allocate Product Licence (<abbr title="Product Licence">PL</abbr>) numbers to <abbr title="Parallel Distribution Notices">PDNs</abbr> based on the existing practice for determining how many separate national licences are needed across a product range. All pack sizes will be covered by a single <abbr title="Product Licence">PL</abbr> number.</p>

<p><abbr title="Parallel Import Licences">PILs</abbr> will be valid for a single source country and a separate <abbr title="Parallel Import Licence">PIL</abbr> will be issued for each source country you request.</p>

<p>There is no fee associated with the conversion from a <abbr title="Parallel Distribution Notice">PDN</abbr> to a Great Britain <abbr title="Parallel Import Licence">PIL</abbr>. However, a periodic fee of £307 will be due on 1 April 2021 for each <abbr title="Parallel Import Licence">PIL</abbr> requested unless a request to cancel the <abbr title="Parallel Import Licence">PIL</abbr> on 31 March 2021 has been notified to <abbr title="Medicines and Healthcare products Regulatory Agency">MHRA</abbr> (<a href="mailto:plpi@mhra.gov.uk" class="govuk-link">plpi@mhra.gov.uk</a>) no later than 31 December 2020.</p>

<p>This is consistent with current periodic fee conditions.</p>

<h2 id="detailed-description-of-the-process-for-convertingpdnstopils">Detailed description of the process for converting <abbr title="Parallel Distribution Notices">PDNs</abbr> to <abbr title="Parallel Import Licences">PILs</abbr>
</h2>

<h3 id="actions-to-take-if-you-are-a-pil-holder">Actions to take if you are a <abbr title="Parallel Import Licence">PIL</abbr> holder</h3>
<p><abbr title="Parallel Import Licences">PILs</abbr> are being issued as a replacement for <abbr title="Parallel Distribution Notices">PDNs</abbr> (which will no longer be valid in Great Britain) and will be issued to the holder of the <abbr title="Parallel Distribution Notice">PDN</abbr>.</p>

<p>The <abbr title="Parallel Distribution Notice">PDN</abbr> holder will need to have a company number allocated by <abbr title="Medicines and Healthcare products Regulatory Agency">MHRA</abbr> as this forms part of the <abbr title="Product Licence">PL</abbr> number which will be allocated to each <abbr title="Parallel Import Licence">PIL</abbr>.</p>

<p>If you do not already have a <abbr title="Medicines and Healthcare products Regulatory Agency">MHRA</abbr>-allocated company number please contact <a href="mailto:plpi@mhra.gov.uk" class="govuk-link">plpi@mhra.gov.uk</a> as soon as possible for instructions on how to apply for a number.</p>

<p><abbr title="Parallel Import Licence">PIL</abbr> holders will need to be established in the UK. If you are a <abbr title="Parallel Distribution Notice">PDN</abbr> holder not established in the UK, but you have an associated company established in the UK which you would like to be the holder of your <abbr title="Parallel Import Licences">PILs</abbr>, please <a href="mailto:plpi@mhra.gov.uk" class="govuk-link">contact <abbr title="Medicines and Healthcare products Regulatory Agency">MHRA</abbr></a> as soon as possible to make this arrangement.</p>

<p>If you do not have an associated, UK-based company you will need to notify <a href="mailto:plpi@mhra.gov.uk" class="govuk-link"><abbr title="Medicines and Healthcare products Regulatory Agency">MHRA</abbr></a> before the end of a period of 4 weeks from the end of the transition period of the name, address, telephone number and email address of an individual who resides and operates in the UK and who may be contacted in respect of any matter relating to the <abbr title="Parallel Import Licence">PIL</abbr>.</p>

<p>You will also need to establish a company in the UK before the end of a period of 24 months from the end of the transition period.</p>

<p><a href="mailto:plpi@mhra.gov.uk" class="govuk-link">Contact <abbr title="Medicines and Healthcare products Regulatory Agency">MHRA</abbr></a> as soon as this company has been allocated a number by <abbr title="Medicines and Healthcare products Regulatory Agency">MHRA</abbr> and we will transfer your <abbr title="Parallel Import Licences">PILs</abbr> to the new company for no fee.</p>

<h3 id="how-to-opt-in">How to opt in</h3>
<p><abbr title="Parallel Distribution Notice">PDN</abbr> holders have been provided with a list of <abbr title="Parallel Distribution Notices">PDNs</abbr> understood to be valid on 31 December 2018. This list will be updated before the end of the transition period.</p>

<p>Check this list very carefully and please <a href="mailto:plpi@mhra.gov.uk" class="govuk-link">notify <abbr title="Medicines and Healthcare products Regulatory Agency">MHRA</abbr></a> of any discrepancy.</p>

<p>Some <abbr title="Parallel Distribution Notices">PDNs</abbr> refer to <abbr title="European Union">EU</abbr> licence numbers which are not listed in the current product information available on the EMA website. These presentations may no longer be valid and  <abbr title="Parallel Import Licences">PILs</abbr> will not be issued for them unless you specifically request one.</p>

<p>The list includes a column for the source countries you want to use for each product. A separate <abbr title="Parallel Import Licence">PIL</abbr> will be issued for each source country you request. If you do not want your  <abbr title="Parallel Distribution Notice">PDN</abbr> for any product converted to a <abbr title="Parallel Import Licence">PIL</abbr>, please enter “none” in this column.</p>

<p>Return the completed list as soon as possible to <a href="mailto:plpi@mhra.gov.uk" class="govuk-link">plpi@mhra.gov.uk</a>.</p>

<p>You must return the list no later than 21 days after the end of the transition period if you wish to take part in the conversion process. It will not be possible to convert further <abbr title="Parallel Distribution Notices">PDNs</abbr> after the end of this 3-week period and a fresh application for a parallel import licence would be necessary, with the associated fee payable.</p>

<h3 id="how-to-request-further-information-for-companies-involved-in-repacking">How to request further information for companies involved in repacking</h3>
<p><abbr title="Parallel Import Licences">PILs</abbr> require some additional information about the companies involved in the repacking process, including the supplier from whom the product is obtained and the companies involved in importing, repacking, batch release, storing and distributing the product.</p>

<p>Supplier information should be addressed by completing a “supplier commitment”, signed by a director of the Parallel Importing company. This is a commitment by the importing company to confirm validity of authorisations (e.g. WDA) and to record details of the source of each batch of product repacked. For details of the wording required, please contact  <a href="mailto:plpi@mhra.gov.uk" class="govuk-link">plpi@mhra.gov.uk</a>. This commitment must be returned before any <abbr title="Parallel Import Licence">PIL</abbr> numbers can be issued and no later than 4 weeks after the end of the transition period.</p>

<p>Companies involved in repacking are best managed using a “Company Functions List”. This can be updated at any time by submitting an updated list to <a href="mailto:plpi.admin@mhra.gov.uk" class="govuk-link">plpi.admin@mhra.gov.uk</a>. The latest list will be applied when a new <abbr title="Parallel Import Licence">PIL</abbr> is granted. Please contact <a href="mailto:plpi@mhra.gov.uk" class="govuk-link">plpi@mhra.gov.uk</a> for a template and example document. This information must be returned before any <abbr title="Parallel Import Licence">PIL</abbr> numbers can be issued and no later than 4 weeks after the end of the transition period.</p>

<h3 id="issue-of-pl-numbers">Issue of <abbr title="Product Licence">PL</abbr> numbers</h3>
<p>As soon as possible after receipt of the list of <abbr title="Parallel Import Licences">PILs</abbr> you require, <abbr title="Medicines and Healthcare products Regulatory Agency">MHRA</abbr> will return an updated list which includes a <abbr title="Product Licence">PL</abbr> number allocated to each product/source country requested.</p>

<h3 id="after-the-end-of-the-transition-period">After the end of the transition period</h3>
<p>Immediately after the end of the transition period you may continue to repack and release those products for which you have requested a <abbr title="Parallel Import Licence">PIL</abbr> using labels and leaflets consistent with the latest annex on the <abbr title="European Medicines Agency/European Commission">EMA/EC</abbr> website and carrying the <abbr title="European Union">EU</abbr> licence number.</p>

<p>Products for which you have not requested a <abbr title="Parallel Import Licence">PIL</abbr> may not be released after the end of the transition period.</p>

<p>Once you have received your list of <abbr title="Parallel Import Licence">PIL</abbr> numbers you should update the labels and leaflet to use these numbers as soon as practicable.</p>

<p>You should continue to monitor the <abbr title="European Medicines Agency/European Commission">EMA/EC</abbr> website and update the labels and leaflet used in your released product to remain consistent with the latest annex on the <abbr title="European Medicines Agency/European Commission">EMA/EC</abbr> website.</p>

<h3 id="receipt-of-pils">Receipt of <abbr title="Parallel Import Licences">PILs</abbr>
</h3>
<p>We expect that it will take some months to issue all of the <abbr title="Parallel Import Licences">PILs</abbr> required. They are likely to be produced on a ‘by product’ rather than a ‘by importer’ basis.</p>

<p>The <abbr title="Parallel Import Licences">PILs</abbr> produced may use a substitute UK reference MA to allow cases to be created in our licence management system before the relevant UK MA for the reference product has been issued. A change of UK reference product variation will be applied to each <abbr title="Parallel Import Licence">PIL</abbr> by <abbr title="Medicines and Healthcare products Regulatory Agency">MHRA</abbr> at no fee at a later date.</p>

<p>The <abbr title="Parallel Import Licences">PILs</abbr> produced as part of this process will use the <abbr title="European Medicines Agency/European Commission">EMA/EC</abbr> annexes for the label and leaflet documents. No “user test” of the patient leaflet will be required.</p>

<h3 id="pil-maintenance">
<abbr title="Parallel Import Licence">PIL</abbr> maintenance</h3>
<p>Once a <abbr title="Parallel Import Licence">PIL</abbr> for a converted product is issued the established Parallel Import variation process applies. Variations should be submitted and approved before an affected product is released, unless the change falls within the Tell-and-Do scheme. Scans of samples should be submitted when required.</p>

<p>The first variation affecting labels and/or leaflets must be accompanied by a mock-up of the respective document(s). In the case of labels this must begin with the label summary sheet. Please contact <a href="mailto:plpi@mhra.gov.uk" class="govuk-link">plpi@mhra.gov.uk</a> for a template.</p>

<h2 id="further-information">Further information</h2>

<p>Please contact <a href="mailto:plpi@mhra.gov.uk" class="govuk-link">plpi@mhra.gov.uk</a> if you have any questions about this process.</p>

</div>
</div>


      <div class="responsive-bottom-margin">
        <div class="app-c-published-dates " lang="en">
    Published 1 September 2020
</div>

      </div>

      <div data-sticky-element class="app-c-contents-list-with-body__link-wrapper">
        <div class="app-c-contents-list-with-body__link-container">
          <a class="govuk-link app-c-back-to-top dont-print" href="#contents">
    <svg class="app-c-back-to-top__icon" xmlns="http://www.w3.org/2000/svg" width="13" height="17" viewbox="0 0 13 17">
      <path fill="currentColor" d="M6.5 0L0 6.5 1.4 8l4-4v12.7h2V4l4.3 4L13 6.4z"></path>
    </svg>
    Contents
</a>

        </div>
      </div>
  </div>
  </div>
  
<div class="govuk-grid-column-one-third">
  
<div class="gem-c-contextual-sidebar">
    <div class="gem-c-contextual-sidebar__brexit-cta govuk-!-margin-bottom-6" data-module="track-click">
  <h2 class="gem-c-contextual-sidebar__brexit-heading">Transition period</h2>
  <a href="/transition" class="govuk-link" data-track-category="relatedLinkClicked" data-track-action="1.0 Transition" data-track-label="/transition" data-track-options="{"dimension29":"Find out what it means for you"}">Find out what it means for you</a>
</div>



    
  <div class="gem-c-related-navigation">

      <h2 id="related-nav-related_items-c822e70a" class="gem-c-related-navigation__main-heading" data-track-count="sidebarRelatedItemSection">
        Related content
      </h2>




      <nav role="navigation" class="gem-c-related-navigation__nav-section" aria-labelledby="related-nav-collections-c822e70a" data-module="gem-toggle">

    <h3 id="related-nav-collections-c822e70a" class="gem-c-related-navigation__sub-heading gem-c-related-navigation__sub-heading--sidebar" data-track-count="sidebarRelatedItemSection">Collection</h3>

  <ul class="gem-c-related-navigation__link-list" data-module="track-click">


        <li class="gem-c-related-navigation__link"><a class="gem-c-related-navigation__section-link gem-c-related-navigation__section-link--sidebar" data-track-category="relatedLinkClicked" data-track-action="1.1 Collection" data-track-label="/government/collections/mhra-post-transition-period-information" data-track-options="{"dimension28":"1","dimension29":"MHRA post-transition period information"}" href="/government/collections/mhra-post-transition-period-information">MHRA post-transition period information</a></li>

  </ul>
</nav>

  </div>



</div>

</div>

</div>


  <div class="govuk-grid-row">
    <div class="govuk-grid-column-two-thirds">
        
  <div class="gem-c-contextual-footer">
    
  <div class="gem-c-related-navigation">





      <nav role="navigation" class="gem-c-related-navigation__nav-section" aria-labelledby="related-nav-topics-7448045a" data-module="gem-toggle">

    <h2 id="related-nav-topics-7448045a" class="gem-c-related-navigation__sub-heading gem-c-related-navigation__sub-heading--footer" data-track-count="footerRelatedItemSection">Explore the topic</h2>

  <ul class="gem-c-related-navigation__link-list" data-module="track-click">


        <li class="gem-c-related-navigation__link"><a class="gem-c-related-navigation__section-link gem-c-related-navigation__section-link--footer" data-track-category="relatedLinkClicked" data-track-action="1.1 Explore the topic" data-track-label="/topic/medicines-medical-devices-blood/marketing-authorisations-variations-licensing" data-track-options="{"dimension28":"1","dimension29":"Marketing authorisations, variations and licensing guidance"}" href="/topic/medicines-medical-devices-blood/marketing-authorisations-variations-licensing">Marketing authorisations, variations and licensing guidance</a></li>

  </ul>
</nav>

  </div>

  </div>


    </div>
  </div>